Anaptysbio (ANAB) Capital Expenditures (2016 - 2026)
Anaptysbio (ANAB) reported Capital Expenditures of $17000.0 for Q1 2026, down 51.43% on a YoY basis from $35000.0 in Q1 2025, and up 1600.0% quarter-over-quarter from $1000.0 in Q4 2025.
Anaptysbio (ANAB) Capital Expenditures (2016 - 2026) Analysis & Trends
Anaptysbio has reported Capital Expenditures for 11 years, with the latest figure at $17000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 51.43% year-over-year to $17000.0; the trailing twelve-month figure through Mar 2026 stood at $69000.0 (down 81.15% YoY), and the FY2025 full-year result was $87000.0, down 75.7% from the prior year.
- Capital Expenditures for Q1 2026 stood at $17000.0, up from $1000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $528000.0 in Q4 2023, with the low at -$123000.0 in Q2 2023.
- Historically, Capital Expenditures has averaged $83705.9 across 5 years, with a median of $35000.0 in 2024.
- The largest YoY upside for Capital Expenditures was 821.05% in 2023 against a maximum downside of 207.89% in 2023.
- Anaptysbio's Capital Expenditures stood at $126000.0 in 2022, then surged by 319.05% to $528000.0 in 2023, then tumbled by 50.19% to $263000.0 in 2024, then slumped by 99.62% to $1000.0 in 2025, then jumped by 1600.0% to $17000.0 in 2026.
- The last three Capital Expenditures figures came in at $17000.0 (Q1 2026), $1000.0 (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Dec 31, 2023 | 528,000.00 |